TrialCritical care medicine2018
Mortality Benefit of Recombinant Human Interleukin-1 Receptor Antagonist for Sepsis Varies by Initial Interleukin-1 Receptor Antagonist Plasma Concentration.
Nuala J Meyer et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.
54 papers cite it
this paperpooled itcites it